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Smart drug delivery platforms such as designer liposomes can be used to enhance 
medicinal properties by enabling control over the time and location of therapeutic 
cargo release.  This can be achieved by designing liposomes that respond to 
different stimuli by releasing encapsulated contents.  Specifically, this work 
focuses on the synthesis of ion recognition lipid switches.  These lipids are 
designed such that their physical properties are altered upon chelation of a given 
metal ion, in this case Zn2+, becoming membrane destabilizing upon molecular 
recognition.  This contributes to the current state of passively controlled release, 
where pathophysiological conditions associated with a diseased site are used to 
control spatiotemporal release of therapeutic cargo.  The use of molecular 
recognition events to effect conformational change and thus cargo release is a 
newly emerging field of research.  Here, a panel of zinc recognition lipids based 
on known zinc chelating moieties including trispicoylamine (TPA) and N,N,N′,N′-
Tetrakis(2-pyridylmethyl) ethylenediamine (TPEN) were synthesized and their 
release potential analyzed.  With incorporation into a liposome platform, these 
lipids can be used to enhance the selectivity of release at diseased cells exhibiting 
elevated zinc concentrations including ischemic tissues, neurodegenerative 
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CHAPTER ONE  
LIPIDS AND LIPOSOMES:  PROPERTIES, STRUCTURES, AND 
GENERAL INFORMATION 
Lipids are unique biomolecular structures, each with a specific set of physical and 
chemical properties.  Via their self-assembly into liposomes, lipids can be 
harnessed for desired applications in molecular recognition and drug delivery.  
Liposomes are advantageous on this front due to their controllable size, potential 
for surface modifications, non-immunogenicity, and ability to solubilize multiple 
drug types.  First, we will discuss the general physical attributes of lipids and 
biologically relevant lipids and their functions.  Then, we will discuss the power of 
the liposome as a drug delivery platform.  Finally, we will dive into synthetic lipids 
and their numerous applications.    
1.1. General Structure and Properties of Lipids  
Lipids are defined by their amphiphilic structures.  When dispersed in aqueous 
media, they spontaneously form aggregates driven by the disparity of polarities 
that exist within the structure.  Each lipid is composed of a polar (hydrophilic) 
headgroup and a nonpolar (hydrophobic) tail region, as depicted in Figure 1.  
Lipids have an overall shape based on the size ratio between these two sections 
of the structure.  Lipids with varying molecular shapes will form different self-
assembled materials to maximize attractive properties when dispersed in 
aqueous media.  The lipid shapes fall into one of three general categories:  
cylinder, cone, or wedge.  These shapes are calculated via the shape parameter 
(S), as defined in equation 1.9  The shape of the lipid will determine its membrane   
forming capabilities.  The different lipid shapes and their resultant aggregate 
formations are shown in Figure 1.  When lipids possess S=1, they exhibit 
cylindrical shapes and are membrane forming with polar headgroups of  
𝑆 =  
 𝑐𝑟𝑜𝑠𝑠−𝑠𝑒𝑐𝑡𝑖𝑜𝑛𝑎𝑙 𝑎𝑟𝑒𝑎 𝑜𝑓 𝑝𝑜𝑙𝑎𝑟 ℎ𝑒𝑎𝑑𝑔𝑟𝑜𝑢𝑝 𝑥 𝑙𝑖𝑝𝑖𝑑 𝑙𝑒𝑛𝑔𝑡ℎ
𝑙𝑖𝑝𝑖𝑑 𝑣𝑜𝑙𝑢𝑚𝑒



































Figure 1.  Lipid structure and shape properties.  
a) The general structure of a lipid.  Lipids are composed of (A) a hydrophobic tail 
region consisting of alkyl tails with varying degrees of unsaturation (B) a linking 
group between tail and head and (C) a polar head group. b) Lipid shapes and their 




approximately the same diameter as the lipid tails. When dispersed in aqueous 
media, these lipids preferentially form bilayer materials including spherically 
shaped liposomes.  These lipid bilayers close themselves into vesicles in order to 
maintain separation of their hydrophobic tails from the aqueous media which 
forms an aqueous pocket inside of the lipid bilayer.  Lipid vesicles include 
unilamellar vesicles, also called liposomes, and multilamellar vesicles, which are 
large vesicles containing smaller vesicles within their aqueous core.  The 
advantages and properties of these lipid vesicles will be discussed at length in a 
future section.   
 
When S>1, lipids take on a cone shape.  These lipids have a larger headgroup 
radius as compared to their tail area, and as a result favor assembly into micelles 
in aqueous solution.  Micelles lack the aqueous inner pocket of liposomes with 
instead their inner layer being composed of the hydrophobic tails.  However, they 
operate under the same properties to shield their hydrophobic tails from aqueous 
media.  The final lipid shape is the inverted cone.  These lipids possess a small, 
usually highly charged, headgroup with a comparably large hydrophobic region, 
giving them a shape parameter of S<1.  The lipids in this category induce negative 
curvature in a membrane environment, and preferentially self-assemble into 
inverted micelles.  Here, the hydrophilic headgroups form the inner core with the 
hydrophobic tails extending outward and composing the outer layer.  In the same 
way that bilayers will self-assemble into liposomes to shield their hydrophobic tails 
from aqueous conditions, inverted micelles will aggregate into an inverted 
hexagonal phase structure, where multiple inverted micelles come together tail-
to-tail.  This shields the outer hydrophobic layer of the inverted micelle from 
aqueous conditions.  Of these three macrostructures, liposome, micelle, 
hexagonal phase, the liposome presents the most interesting possibility as a drug 
delivery platform due to the ability to manipulate their membrane properties.  By 
exploiting lipids of different shapes, membrane stability can be controlled and 




liposomal controlled release platforms, where switching from membrane forming 
(S=1) to non-bilayer (S>1) lipids is the main method for the release of 
encapsulated cargo.         
1.2. Lipids in the Biological Setting 
Natural lipids, those produced through biological processes, are key cell to viability.  
They compose 50% of the mass of eukaryotic cellular membranes and are 
responsible for the membrane structural integrity.10  It is the unique structure of 
lipids that makes them suitable for membrane formation, as previously discussed.  
Non-membrane supporting lipids, such as inverted cone shaped lipids, are also 
present in the biological milieu, but only at lower percentages that don’t disturb 
bilayer stability.  These serve important and tightly regulated functions within the 
cell as well.  Natural lipids fall into two main categories, glycerophospholipids and 
sphingolipids.  These groups are determined by which molecule the lipids are 
derived from, glycerol or sphingosine, respectively.  Sterols, such as cholesterol, 
are also grouped under the definition of lipids because they are also amphiphilic 
membrane components, though they don’t follow the same general structure of 
other lipids.  Nevertheless, cholesterol is an abundant membrane component and
 
Figure 2.  The structures of some biologically relevant lipids. 
Polar headgroups for DAG, PA, PS, PIPns, PE, and PC are as shown.  
Hydrophobic tail length and degree of saturation vary between each lipid.  In 






important to membrane integrity.  Lipids dictate numerous processes in the cell, 
performing structural and functional roles.  The exact structures of natural lipids 
dictate their function within the cell.  The structures of some biologically relevant 
lipids are shown in Figure 2.  The variation in headgroup size and functionality 
determines the function of each lipid.  One of the most notable structural lipids is 
phosphatidylcholine (PC).  PC is the most abundant lipid in eukaryotic cell 
membranes and is the classical example of a cylindrical shaped lipid, favoring 
bilayer formation.  The remainder of the cellular membrane is composed of less 
abundant lipids that exhibit functional roles within the cell, proteins, and other 
membrane stabilizing molecules like cholesterol.  PC is key to liposomal drug 
delivery platforms as well, as it serves as a main bulk lipid for many of the lipid 
formulations used to produce therapeutic liposomes.   
 
Functional lipids, generally termed signaling lipids, represent the other branch of 
lipids within the cell.  Through recruitment of proteins to the membrane surface, 
through either intra- or extra-cellular binding events, these lipids can regulate cell 
activities controlling such processes as cell proliferation, apoptosis, metabolism, 
gene expression, and membrane trafficking.11-13  The specific interactions between 
lipids and proteins that mediate these processes can be as simple as a monovalent 
binding event between a lipid and its target protein, or as complex as a 
microdomain of lipids acting together to bind protein in a  multivalent fashion.14   
These complex interactions recruit proteins to the cell surface and trigger a 
cascade of important processes within the cell.  Thus, aberrations in the interaction 
of these vital signaling lipids with their corresponding peripheral proteins can lead 
to the onset of diseases such as cancer, inflammation, autoimmunity, and 
degenerative diseases.11, 15  These intricate interactions have led to a burgeoning 
field involving the study of the activities of signaling lipids.   
 
Many of the notable signaling lipids are glycerophospholipids including 




phosphatidylethanolamine (PE), and phosphatidylinositol polyphosphates 
(PIPns).11, 15-16  DAG, the simplest of the signaling lipids, controls vital processes 
within the cell.  DAG activates protein kinase Cs (PKCs), enzymes that control the 
cell cycle and exhibit tumor suppressing activity.17-19  PKC is one of the most highly 
misregulated proteins in cancer.  Thus, tightly regulated DAG activity is necessary 
for the maintenance of human health.  PA interacts with Raf-1, a kinase involved 
in cancer.20  In healthy cells, PS is found mainly in the inner leaflet of the cellular 
bilayer and is only translocated to the outer membrane leaflet, where it recruits 
proteins, to signal apoptosis.21  PIPns regulate vesicular trafficking and modulate 
lipid distribution within the cell by their interaction with lipid transfer proteins.22  
Each of these regulatory functions of lipids help maintain a healthy cellular 
environment.  Again, the abilities of these lipids to stabilize, destabilize, and 
perform signaling roles within the cell are due to their specific shape and chemical 
structure.  This highlights the importance of lipid characteristics not only in the 
biological setting, but when considering synthetically designed lipids.   
1.3. The Liposome as a Drug Delivery Platform 
Liposomes represent a key platform for delivery of drugs within a biological system. 
They exhibit tunable properties in size, surface functionalization, cargo type, 
surface charge, and release mechanism that allow for a customizable platform.  
The properties of liposomes will be discussed below as they relate to their use as 
a nanoscale drug delivery platform. 
1.3.1. Liposome Formation 
Lipids will self-assemble into vesicles when dispersed in aqueous media due to 
their amphiphilic nature.  While these arbitrarily formed vesicles are not formed 
with homogeneous and predictable size or lamellarity, they can subsequently be 
manipulated to be of uniform characteristics.  A popular method for obtaining 
liposomes of reliable size is through thin film formation, hydration, and extrusion.23  




desired liposomal content.  This lipid mixture is dried into a film, removing all 
organic solvent from the sample.  The film is then hydrated with water or an 
aqueous buffer and subjected to freeze/thaw cycles to form large mulitilamellar 
vesicles (MLVs) of various sizes.  The solution of MLVs is subjected to extrusion 
through polycarbonate filters with pores of the desired liposome diameter.  Multiple 
passes through the extrusion filter give liposomes of reliable size.  Generally, 
liposomes are composed of PC, the main bulk lipid of cell membranes.  Other lipids 
including synthetic analogs bearing desired properties or functionalities for the 
specific liposomal platform can also be added to the film composition yielding 
vesicles of desired lipid content.      
 
Liposomes are formed in a variety of sizes depending on the desired application.  
Utilizing different pore sizes in the extrusion step, or other less conventional vesicle 
formation techniques24, liposomes of 20-1000 nm in diameter can be formed.  
Small unilamellar vesicles (SUVs) are from 20-100 nm, large unilamellar vesicles 
(LUVs) are greater than 100 nm in diameter, and giant unilamellar vesicles (GUVs) 
are larger than 1000 nm in diameter.  Generally, liposomes of 100-200 nm are 
utilized for drug delivery applications.  Vesicles of this size have a higher 
propensity to fuse with cell membranes due to the strain exerted on the lipids in 
the highly curved liposome surface. They also benefit from an increased circulation 
time by avoiding the reticulo-endothelial system (RES) longer than their larger 
counterparts.24-25  Structures of this size are also able to make use of the enhanced 
permeability and retention (EPR) effect.  This effect arises since the vasculature 
surrounding rapidly expanding cells, such as tumors, as well as other diseased 
tissues like those in inflammatory diseases and ischemia, have loose junctions 
between the endothelial cells of the blood vessel walls. 26-28  These gaps in the 
vessel lining are 0.1-3 μM in size allowing nanosized structures to leak from the 
blood vessel to the diseased area.  A lack of drainage of lymphatic fluids, another 
hallmark of the EPR effect, allows the leaked nanomaterials to remain at the 




sites versus other common accumulation organs.28  This makes the EPR effect, 
on its own, not a powerful enough phenomenon to effect efficient drug delivery, 
though it can be coupled with other modifications to increase liposomal delivery 
and efficiency.   
 
The ability of liposomes to encapsulate multiple drug types is also an attractive 
factor in their use as a drug delivery platform.  Liposomes can house hydrophobic 
and hydrophilic cargo within the membrane bilayer or the aqueous core, 
respectively.  Prodrugs can also be incorporated via attachment to a synthetic lipid 
at either the head group or as a hydrophobic tail, depending on the nature of the 
drug.  Further examples of this will be provided in the next section.   
1.3.2. Liposomal Surface Modifications 
Modifications to the surfaces of classical liposomes can drastically enhance their 
power as a drug delivery vehicle.  Surface modifications can act as shielding 
groups to protect liposomes from clearance from the body.  Other surface 
modifications can increase the rate of fusion with target cells, while a very 
important group of surface ligands is comprised of active targeting moieties to 
enhance the selectivity for delivery to diseased cells within a complex biological 
mixture.  The main surface modifications are depicted in Figure 3.  Multiple 
surface modifications can be combined in one liposomal platform to enhance the 
overall efficiency of the drug delivery system.   
1.3.2.1. Surface Modifications for Creation of Stealth Liposomes 
Synthetic modifications to bare liposomes can drastically enhance their power as 
a drug delivery vehicle.  Bare liposomes have a short half-life and are quickly 
cleared from the bloodstream by the RES system.29  Though smaller liposomes 
inherently have longer circulation times than larger vesicles, they still have 








Figure 3.  Surface modifications for increased efficiency of liposomal 
drug delivery systems. 
Representative modifications for the creation of stealth liposomes, the increase 
of liposome fusogenicity and cellular uptake, and actively targeted liposomes 
are shown, though multiple modifications to effect each desired outcome are 
available.  Cellular penetrating peptides (CPPs), polyethyleneglycol (PEG), 





modifications can shield the liposome from clearance, thus increasing their half-
life.  These surface modifications act as a physical barrier to keep opsin proteins 
from binding to the surface of the liposome, thus marking them for clearance by 
the immune system.30  Initially, groups such as gangliosides and sialic acid 
derivatives were used to decorate liposomes.25  These are common surface 
markers found on red blood cells, so by mimicking the native cell population of the 
administration route, the liposomes were able to evade the immune response.  
Now, the most common stealth coating is polyethylene glycol (PEG).  Incorporation  
of PEG-PE conjugates into PC based liposomes showed an increase of circulation 
half-life from 30 minutes for bare liposomes to 5 hours in the earliest studies in 
PEGylation.31  PEGylation also decreases the leakiness of liposomes, better 
harboring cargo for less off-site drug interactions.29-30  PEG incorporation is 
relatively simple and there are now commercially available versions of lipids with 
PEG of a range of molecular weights appended to the headgroup.32  Advances in 
PEGylation methods can now give circulation half-lives of 5-16 hours dependent 
on PEG polymer length.29  PEG coatings can be purely polymer based or can be 
terminated with a functional group for further synthetic modification to the cloaked 
liposome surface.  The impetus for this will be covered in the next section.  Overall, 
the size control and potential for surface modification of liposomes help to increase 
circulation time and accumulation at diseased sites by evasion of the RES system 
and taking advantage of the EPR effect. 
1.3.2.2. Surface Modifications for Active Targeting with Liposomes 
Liposomes can be decorated with a variety of small molecules to increase their 
efficacy of delivery through active targeting.  When based solely on the EPR effect, 
liposomes only make it to the general vicinity of the target site.  Surface 
modification with targeting groups will pull these liposomes to the surface of target 
cells, increasing the therapeutic index of the delivery platform.  Binding partners 
with high affinity for ligands found overexpressed or solely expressed on the target 




directly to the liposomal surface through functionalized lipids or attached to the 
reactive end of a PEG-lipid conjugate present in the liposome formulation.  
Presentation outside of the PEG shell effects greater targeting ability, while 
shielding of the targeting moiety within the PEG shell protects the ligand from off 
target binding outside of the desired location.  Still dependent on the EPR effect, 
once the small liposomes have leaked into the interstitial space of the diseased 
tissue, recognition of the targeting group by the cell surface will trigger uptake or 
fusion of the liposome.  Induced removal of the PEG shell after arrival at the target 
site can also aid in delivery, methods of which will be explained shortly.  Ideally, 
the liposome will fuse with the cell surface, dumping its molecular cargo into the 
target cell or be taken in by endocytosis and then effect escape from the endosome 
and cargo release.  Specially formulated fusogenic liposomes increase the 
propensity of membrane-to-membrane fusion to effect cargo delivery while 
avoiding the lytic activity of lysosomes.33 
 
Another class of surface modification that instigates higher cellular uptake in a non-
cell-type specific manner are cell penetrating peptides (CPPs).  CPPs are most 
commonly highly cationic short peptides with transactivator of transcription (TAT) 
and octa-arginine (R8) peptides as representative examples.34  These cationic 
peptides function to enhance permeation of liposomal content into target cells.  
Also, due to their ability to attenuate the surface charge of the liposome, drug 
loading efficiencies for hydrophobic or negatively charged cargo such as siRNA 
are increased with CPP decorated liposomes due to the increased electrostatic 
interactions of these cargo with the surface CPP.34  CPPs can be rendered inactive 
by enzyme removable or light cleavable groups.35-38  This allows the CPP to affect 
its function only at the desired spatiotemporal location with application of the 
correct stimulus.  Spatiotemporal control of liposomal content delivery is a research 





Of heightened interest are the utilization of cell specific ligands for targeted 
delivery.  Folate receptors (FR) are over expressed in their functional form on 
countless types of cancer cells, including ovary, breast, colon, lung, prostate, nose, 
throat, and brain cancers.39  Also, metastatic cancers tend to express FRs at a 
higher rate than non-metastatic cells.40  Likewise, FRs are also highly expressed 
on macrophages involved in inflammatory and autoimmune diseases providing 
multiple potential targets for folate mediated liposome therapies.39  Folic acid 
functionalized liposomes have been successfully applied for the co-administration 
of multiple chemotherapeutics to FR expressing breast cancer cells.41  Many folate 
mediated targeting methods have been successful for the preferred delivery of 
drugs and imaging agents to cancerous, inflammatory and autoimmune diseased 
cells.42-44  One interesting study demonstrated delivery of microbial epitopes to 
cancer cells through folate receptor mediated delivery.  Fusion of the tumor cell 
with the therapeutic liposome led to expression of the epitopes on the cell surface, 
activating the immune system causing cytotoxicity via complement mediated cell 
lysis.45  Other surface markers that have been targeted by liposomal recognition 
include CD123.  This surface marker is overexpressed on acute myeloid leukemia 
(AML) cells and increases cell resistance to apoptosis.  Anti-CD123 monoclonal 
antibodies (mAb) were appended to drug loaded PEGylated liposomes for 
targeting.  Specifically, liposomes that are targeted via mAb or antigen binding 
fragments (Fab’) are termed immunoliposomes.46  Anti-CD123 immunoliposomes 
were able to effect higher rates of cellular uptake and cytotoxicity versus 
nontargeted liposomes.47  CD44 is a classic surface marker of cancer stem cells, 
a subset of cancer cells that promote malignancy and therapeutic resistance.48  
mAbs against CD44 have been integrated into immunoliposome platforms to 
increase targeting and cytotoxicity against this potent cell type.49  Human 
epidermal growth factor receptor-2 (HER2) is another surface ligand of certain 
cancer types that has been harnessed for targeted delivery via antibody mediated 




has the potential to be targeted for more efficient therapeutic delivery of cargo via 
active targeting liposomes.           
1.3.3. Active vs. Passive Release Mechanisms 
While liposomes are effective vehicles for transporting cargo due to their inherent 
amphiphilic nature, the specific release of cargo at the desired location within the 
body is key to an effective drug delivery vehicle.  PEGylation, targeting ligands, 
and modification with CPPs help to increase local concentration and fusogenicity 
of liposomes, but do not directly effect a quick triggered release of drug.  There 
are, however, various methods to trigger cargo release from therapeutic 
liposomes.  These fall into two categories:  active and passive release.  Active 
release relies on some form of external stimulus to effect release of molecular 
cargo while passive release mechanisms utilize internal physiological stimuli, ie 
conditions within the diseased tissue itself, to effect release.  A schematic 
representation of triggered release mechanisms is shown in Figure 4.  Whether 
active or passive, these release mechanisms rely on one of a handful of methods 
for release.  These are membrane restructuring, deshielding of the liposome, 
prodrug activation, lipid reconstruction, and conformational switching.   
1.3.3.1. Active Release Mechanisms 
Active release mechanisms require an input of some external stimulus.  This is 
advantageous in the fact that it limits off target release of cargo.  However, external 
stimuli can be limited by their ability to penetrate through healthy tissue to the 
diseased area.  External stimuli are mainly reliant on photothermal effects, 
including the application of light, heat, ultrasound, or a magnetic field to induce 
release. 
 
Light triggered release can be effected by a number of liposomal features.  
Liposomes loaded with or appended with photosensitizers, such as porphyrin, can 





Figure 4.  A schematic representation of stimuli responsive release of drug cargo from liposomes.   
Liposomes can be loaded with hydrophilic (green) or hydrophobic (purple) cargo in the aqueous core or lipid bilayer, 
respectively.  Prodrugs can also be bound to synthetic lipids at the headgroup as shown in yellow, or integrated as 
a tail unit (not depicted here).  Stimuli responsive lipids (red) can be incorporated for spatiotemporal control of drug 
delivery.  Upon application of stimuli (light, heat, ultrasound, pH change, enzyme, molecular recognition) the drugs 




These ROS will oxidize any unsaturated points in the lipid tails.  This makes the 
lipid tails less hydrophobic, disrupting the membrane bilayer and effecting 
release.51-53  Other methods of light triggered release rely on the light mediated 
degradation of a lipid’s integrity, thereby disrupting the liposome.  Photocleavable 
groups can be incorporated into a synthetic lipid to induce degradation.  In one 
example,an o-nitrobenzyl (ONB) group was incorporated into a synthetic lipid tail.54  
With application of 350 nm light, the ONB group was cleaved, yielding single tailed 
 lipids in the membrane, which are destabilizing to the liposomal integrity. Up to 
80% cargo release of hydrophobic cargo was achieved via this method.  These 
both represent lipid reconstruction methods of drug release.  Photocleavable 
groups can also be used to tether a prodrug to the liposomal surface.  Again, upon 
delivery of the liposome to the desired location a specific wavelength of light can 
be applied locally to stimulate the release and activation of the drug from the 
liposome surface.55  In this way, photochemistry can be utilized to deliver molecular 
cargo from a number of loading sites of the liposome.   
 
Similar to light reactivity, the application of heat itself can cause liposomal release.  
Lipids have a specific phase transition temperature above which they become 
more fluid.  Phase transition temperatures are intrinsic to specific lipids, so required 
temperatures to increase membrane fluidity of a given liposomal formulation can 
be calculated.  Localized heating of the diseased tissue will cause increased 
membrane fluidity, enhancing membrane permeability and effecting release in that 
area.56  Unfortunately, these phase transition temperatures are only a few degrees 
above body temperature.  While higher phase transition temperatures can be 
achieved, the negative side effects associated with the therapeutic application of 
higher temperatures are prohibitive.56  Other examples of thermal effects include 
release through the destabilization of heat sensitive membrane incorporated 
peptides or polymers and the degradation of encapsulated cargo into gaseous 
components forming microbubbles.24, 57  One method to achieve increased 




nanoparticles in the liposomal formulation.  Under application of an alternating 
magnetic field (AMF) the magnetic nanoparticles, generally iron based, will heat 
up, giving upconverted localized heating of the liposomes.24  Ultrasound 
application can destabilize air pockets in the liposome, leading to their escape and 
thus destabilization of the liposomal membrane, ie cargo release.24  All of these 
effects function under general membrane destabilization as their method of 
release.  These represent spatiotemporal controlled external stimuli for drug 
release via exogenous methods.  
 
These mechanisms are hindered by the power of their stimulus.  The depth of 
penetration into living tissue for light, laser, heat or ultrasound require that the area 
for treatment be close to the surface.  This limits therapeutic applicability of these 
systems to certain disease states.  Deep tissue tumors, for example, would not be 
treated efficiently through these methods.  These stimuli can also have negative 
effects on healthy cells.  For example, UV light as a stimulus has the potential to 
harm healthy cells peripheral to the target diseased tissue.  For these reasons, 
passive release mechanisms driven by the physiological differences between 
diseased and healthy tissue provide a less invasive method for effecting release 
at a desired point in the system.    
1.3.3.2. Passive Release Mechanisms 
In passive release, the stimulus for cargo release comes from the diseased tissue 
itself.  These stimuli are mainly changes from normal physiological conditions 
associated with the target disease.  Internal stimuli include lowered pH,  increased 
reducing environment, altered enzyme expression, and increased surface or 
soluble molecule concentrations.  By designing a liposome platform that is 
sensitive to these conditions, it will release therapeutic cargo only where these 
altered physiological stimuli are present.  These internal stimuli don’t suffer from 
the tissue penetration and localization issues of active release mechanisms, as the 




cargo release, the dose requirement can be lowered providing a more desirable 
therapeutic index.   
 
Passive release techniques are a powerful method for harnessing the unique 
microenvironment of the targeted diseased tissue.  Specialized synthetic lipids 
have been designed to take advantage of these conditions.  Lowered pH is one 
hallmark of cancer cells.  As tumor cells rapidly grow, blood vessel formation 
throughout the new tissue is poorly controlled.  This causes a hypoxic, or low 
oxygen, environment in the tumor and surrounding tissues.  To maintain their 
growth in absence of sufficient oxygenation, tumor cells will switch to anaerobic 
metabolic pathways causing an increase in the production of acidic metabolites 
like lactic acid.58  This build up of acidic products causes a lower pH in cancerous 
tissues as compared to healthy tissues.  This difference in conditions can be 
utilized as a trigger for selective release of drug cargo at the desired location.  
Liposome formulations can effect cargo release under acidic conditions by a few 
different mechanisms.  The protonation of susceptible groups such as carboxylates 
can change the electrostatic interactions of the polar headgroups of lipids in a 
bilayer.  By decreasing the charge balance in the polar section of the bilayer, there 
is increased repulsion between headgroups and thus destabilization of the 
membrane.59  This allows for the use of more classical lipids to effect release under 
acidic conditions.   Another avenue to acid triggered release is the implementation 
of synthetic lipids that undergo a conformational change upon acidification.  
Various trans-2-aminocyclohexanol based lipids have been prepared so that 
protonation of the amino group causes a chair flip due to increased stabilization 
via hydrogen bonding of the newly protonated amine (Figure 5).1, 60  In the 
unprotonated chair structure, the alkyl tails were ideally arranged to insert into a 
membrane, and after protonation the tails were maximally separated due to the 
change in conformation from diequatorial to diaxial in respect to the tail 
substitutions (Figure 5).  A di(methoxyphenyl)pyridine based lipid operated 







Figure 5.  Examples of pH responsive conformational lipid switches.   
a)  A trans-2-aminocyclohexanol based lipid switch that undergoes a chair flip 
upon protonation.1  b) A di(methoxyphenyl)pyridine based lipid switch that 
undergoes extreme rotation at the headgroup upon protonation.2  c)  A 





adjacent methoxy groups, which effected maximal separation of the alkyl tails.2  
This changed the orientation of the alkyl tails to one another, increasing the cone 
angle and disrupting the membrane.  Acidic conditions can also be utilized to 
deshield stealth liposomes.  PEGylated liposomes with acid sensitive linkers 
between the PEG polymer chain and the liposomal surface have been developed.  
These lipids were formed into vesicles with DOPE, which forms hexagonal phase 
structures on its own favoring membrane fusion and cargo release.  However, in 
mixtures with PEG-lipid conjugates DOPE can form lamellar structures.61  
Deshielding via the acidic environment revealed the fusogenic, destabilized DOPE 
liposomal surface leading to a phase change from lamellar to hexagonal phase 
and a release of contents.  The induction of non-bilayer lipids, such as with this 
method, is a common route for destabilization of liposomes for cargo release.  
Here, this was achieved through the acid-catalyzed cleavage of vinyl ether, 
diorthoester, and hydrazone linked PEG-PE conjugates.61-63  All of these release 
examples were based on the destabilization of PE based liposomes after the 
removal of the protective and stabilizing factor of the PEG coating.    
 
Reducing conditions can also lead to drug release from liposomes based on 
synthetic modifications to the liposome components such as the incorporation of 
disulfide bonds.  As with the acid sensitive method, disulfide linkages can be added 
between cloaking PEG groups and the liposomal surface.  Upon reduction of the 
disulfide bond, the PEG layer is removed, destabilizing the liposomes and leading 
to liposome aggregation and cargo release.64-66  Various other targeting moieties 
have been coupled with this method, including CPPs such as TAT, whereby the 
removal of the PEG polymer coating in the reductive environment of the diseased 
tissue revealed TAT for increased uptake of the liposomes into cells, rather than 
just destabilization based on the formation of hexagonal phase structures after 
PEG removal.65 
The overexpression of certain enzymes in diseased cell lines has also been 




extracellularly expressed enzymes.  Lipids for this drug delivery platform have 
been modified in similar ways to the other passive release techniques.  That is, 
enzymatic activity can effect drug release by a number of methods:  destabilization 
of the membrane through lipid restructuring, enzymatic removal of a polymer 
(PEG) shielding layer, or activation of a prodrug via enzymatic cleavage.67  
Phospholipase sPLA2 can effect cargo delivery through the restructuring of PE.  
Enzymatic cleavage of PE into lysoPE and stearic acid prompted membrane 
destabilization and cargo release from liposomes composed of PE, PC, and 
PEGylated PE.  These were 2.5 times more potent than non-targeted liposomes.68  
sPLA2 is upregulated in prostate, breast, and pancreatic cancers as well as 
infections where the enzyme is excreted by several bacteria types.67  Lipid based 
prodrugs where the enzymatically cleavable tail is replaced with a prodrug have 
also been designed and applied.  Various hydrophobic drugs were successfully 
released via phospholipase cleavage of the prodrug.  This method increases 
encapsulation efficiency of lipophilic drugs as well as local concentration of drug 
upon triggered release.67   
The matrix metalloproteinases (MMPs) compose another family of enzymes 
upregulated in cancer, where they are associated with angiogenesis.  MMPs 
cleave specific peptide sequences, which can be incorporated into PEGylated 
liposomes as a deshielding technique.  MMP sensitive linkers were inserted as a 
linker between PE and PEG as an effective means of dePEGylation at target tissue 
sites.  These specific liposomes also had mAb and CPP functionalities that were 
revealed upon deshielding, providing a multitargeted platform for drug delivery.69  
The ability to combine multiple shielding, deshielding, targeting, and release 
triggers into a single liposomal platform is one of the desirable advantages to 
liposomes as a drug delivery system.   
1.4. Summary and Implications 
Designer liposomes are utilized to control the spatiotemporal release of therapeutic 




into the liposomal composition.  These modifications serve to increase circulation 
time, provide a targeted accumulation of therapeutic liposomes at diseased cells, 
and trigger release of drug cargo at the desired time and location.  Currently, 
release from liposomes can be controlled via active (external) or passive (internal) 
stimulus as summarized above.  Many of these methods rely on the production of 
non-bilayer lipids as the means of membrane destabilization to effect release.  
Passive release techniques present a unique situation where the characteristics of 
diseased cells can be harnessed to trigger the release of drugs or therapeutic 
cargo.  Current work in this area relies mainly on pH differences between healthy 
and cancerous cells to trigger a membrane change and effect release.  Molecular 
recognition events would hypothetically create a more specific release potential 
based on the concentrations of metabolites, enzymes, ions, or other biomolecules 
that are unique to the target site.  This work seeks to utilize molecular recognition 
of increased ion concentrations to differentiate between healthy and diseased 
cells.  These molecular recognition events will cause the bound lipid analog to 
undergo a conformational change leading to destabilization of the liposome 
membrane and thus leakage of encapsulated cargo.  Currently, no controlled 
release strategies have been approved for clinical use, thus advances in controlled 
release platforms would contribute to the current toolbox of available liposomal 
release tactics expanding the applicability of liposomes to treat various diseases.   





CHAPTER TWO  
DESIGN AND SYNTHESIS OF ION RESPONSIVE LIPIDS FOR 
CONTROLLED RELEASE APPLICATIONS 
2.1. Project Summary 
The goal of this project is to synthesize a panel of lipid switches for zinc recognition.  
These lipids, upon binding of Zn2+, will undergo a conformational change proposed 
to shift the lipid shape from a membrane supportive structure to a non-bilayer lipid 
leading to the destabilization of the surrounding membrane environment.  By 
including these lipid switches in liposomal formulations, we can control membrane 
stability, and by extension content release, based on the ion concentration of the 
surrounding media.  This platform is of specific interest for delivery of therapeutic 
cargo to diseased tissues in which local zinc concentrations are elevated including 
ischemic tissues, neurodegenerative diseases, and certain cancer types.3-8  
Through this platform, we propose to harness a physiological difference between 
healthy and diseased tissues, creating a new passive release technology.        
2.2. The Biological Role of Zinc 
Zinc is an essential element present at trace amounts in the human body.  The 
bulk of zinc is bound to proteins, with approximately 10% of all human proteins 
containing zinc in its bound state.70  In these proteins it plays structural and 
catalytic roles, being involved in the function of approximately 300 different 
enzymes.71  The remaining minor fraction of zinc exists as its labile ion form.  Free 
zinc is present at very low concentrations within the cytosol of cells, at estimated 
subnanomolar concentrations.  The bulk of free zinc is tightly regulated in storage.  
Zinc importer proteins (ZIP) and zinc transporter proteins (ZnT) act to shuttle zinc 
in and out of the cytosol, respectively.  These proteins are present in the cellular 
membrane as well as vesicular membranes including those of storage vesicles, 
endoplastic recticulum, mitochondira, and the golgi where they shuttle excess zinc 




by reversible binding to metallothionein (MT), a metal binding protein that will 
release free zinc upon receiving the appropriate signal.72-73  Free zinc 
concentrations are increased in neuronal cells undergoing apoptosis as a 
consequence of ischemia or trauma in the brain.3  Zinc dysregulation is also 
involved in certain cancers.4-6  Chelation therapies have been applied for the 
treatment of Alzheimer’s disease, further providing that zinc is a worthy target for 
a therapeutic platform.7-8  In this work, a lipid switch will be designed so that upon 
recognition of Zn2+ conformational changes will drive cargo release.   
2.3. Molecular Recognition Events as Stimuli for Cargo Release 
via Lipid Switches 
This work specifically focuses on the utilization of lipid switches as a cargo release 
tactic, a newly developing approach based on the molecular recognition of 
upregulated ions or metabolites to effect cargo release from a liposome.  This 
research will serve to expand the current available toolbox of controlled release 
tactics which is currently limited.  Various physiological stimuli for cargo release 
have been discussed thus far, and while ion recognition falls into that category, it 
will be covered in detail now.  Lipid switches, similar to the conformational release 
lipids discussed in the pH responsive section, rely on membrane destabilization to 
effect release.  Recognition of the target molecule by a synthetic lipid switch leads 
to a conformational change of the lipid and thus a change in its membrane support 
characteristics.  This method has been applied for the recognition of 
overexpressed surface markers of cancer cells, altered membrane compositions, 
and upregulated ion concentrations in diseased cells.74-76  A boronic acid lipid was 
synthesized for molecular recognition of carbohydrates, which are overexpressed 
on cancer cell surfaces.  Liposomes containing this molecular recognition lipid 
were shown to bind and enhance cellular delivery.76  Liposomal membrane 
restructuring via multivalent recognition of carbohydrate moieties was the primary 
method of cargo delivery, where increased movement of the recognition lipid within 




Ion recognition events are another interesting method for membrane 
destabilization.  For example, a calcium-responsive lipid switch was designed such 
that upon calcium chelation the lipid underwent a conformational change from 
membrane supportive to membrane destabilizing.  Here, a previously described 
calcium sensor77 was modified to suit the lipid requirement for membrane insertion.  
Alkyl tails were appended to the calcium sensor rather than a fluorescent indicator 
as in the original sensor.   Through chelation with the carboxylate moteifs present 
at the lipid head, binding dependent cargo release was achieved (Figure 6) .74  The 
lipid switches including the pH responsive examples discussed in section 1.3.4.2. 
undergo similar conformational changes where protonation and hydrogen bonding 
can be considered a type of molecular recognition.1-2, 60  Specific to the interest of 
this work, other ion responsive lipids have been seen in literature as well.  These 
include copper and zinc responsive lipid switches.  A bispidinone based lipid was 
utilized to recognize copper via electrostatic interactions between nitrogens and  
Cu2+, effecting a boat-to-chair conformational change at the headgroup causing 
convergence of the alkyl tails.  Even though the tails became less distanced from 
one another via this chelation event, release was still seen with the application of 
Cu2+.  This shows that perturbation of the membrane in general by conformational 
changes may be enough of a driving force for efficient cargo release.  A final 
example on ion chelation operates slightly differently than the previous examples.  
Dimeric zinc chelates of a sugar based lipid preferentially formed liposomes, where 
treatment of liposomes containing the zinc chelate with acid caused removal of the 
zinc from complexation via protonation, which effected cargo release.78  These 
pre-complexed lipids were found to increase delivery of internalized cargo to 












Figure 6.  Calcium triggered lipid switch 
Lipid switch based on a fluorescent calcium sensor, indo-1.  Titration with Ca2+ 
effected 65% release of hydrophobic dye nile red from liposomes containing 10% 





2.4. Design Inspiration and Considerations for Zinc Switchable 
Lipids 
In regards to the design of a zinc responsive lipid switch, we drew inspiration from 
previous work with the study of zinc chelating molecules.  Trispicoylamine (TPA) 
and N,N,N′,N′-Tetrakis(2-pyridylmethyl) ethylenediamine (TPEN) are two well-
known zinc chelators (Figure 7).  They bind zinc with high affinity with dissociation 
constants of 10 pM and 0.3 fM, respectively.79  Also, these chelating groups bind 
preferentially to zinc over other biologically available divalent transition metal 
cations such as iron or manganese, as predicted by the Irving-Williams series.79-80  
These nitrogen based chelators vary in the pKa of their central tertiary nitrogens, 
wherein TPA exhibits a pKa of 6.17 and TPEN has a pKa 7.19.  This makes TPA 
less likely to be protonated at physiological pH, resulting in more operational 
chelator available in the biological setting.79  These pyridal core structures have 
been utilized to visualize zinc concentrations in live cells and tissues.81-84  By 
appending a fluorescent molecule to the general TPA structure, a fluorescence 






Figure 7:  Zinc cheating molecules. 
Structures of pyridal zinc chelating molecules TPA and TEPN.  Zinpyr-1 is a 






For our purposes, we do not require a fluorescent indicator.  We instead envision 
using the chelator core structure as the polar headgroup of a lipid.  Rigidly attached 
tails will build in the conformational change aspect that is required of the lipid and 
thus effect release of cargo upon binding of zinc to the chelating lipid core (Figure 
8).  In this manner we will be able to control membrane stability and by extension 
cargo delivery based on membrane composition of the given liposome.  In the next 
sections, synthesis of lipids based on these design principles will be discussed. 
2.5. Design and Synthesis of Zinc-Responsive Lipid ZnR1 
2.5.1. ZnR1 Synthesis 
Zinc responsive lipid ZnR1, Figure 9, was the original design for a zinc triggered 
lipid.  In this structure, a TPA core is appended with three alkyl tails attached via 
amide linkages.  These tails are attached at the 4-position of the pyridine subunit, 
allowing the alkyl tails to rest comfortably within a membrane bilayer when in the 
unbound state.    
 
Synthesis of ZnR1 (Figure 9) began with the diesterification of commercially 
available 2,4-pyridinedicarboxylic acid.  This acid catalyzed ester formation 
quantitatively gave intermediate Z1.1.85  This diester intermediate then underwent 
a selective reduction with sodium borohydride to give aldehyde Z1.2.86  The 
aldehyde functionality was utilized to perform successive reductive aminations in 
a one pot approach, yielding the TPA core bearing three pyridine esters in a 49% 
yield as intermediate Z1.3.87  This gave the TPA core in good yield over few steps, 
as compared to previous attempts to form the TPA core via successive SN2 
substitution reactions (see further discussion below).   
 
The addition of the amide tails was approached from a number of synthetic angles.  






Figure 8.  Proposed membrane disruption by zinc responsive lipid 
switches 
Lipid targets ZnR2.2 (panel a, TPA based) and ZnR3.1 (panel c, TPEN based) 
are depicted in their unbound state, inserted comfortably into the membrane 
bilayer.  Upon treatment with Zn2+, the lipid switches are proposed to bind zinc in 
a 1:1 ratio to give ZnR2.1-Zn2+ (panel b) and ZnR3.1-Zn2+ (panel d). The lipid 
switches are designed such that they take on non-bilayer lipid shapes upon 
binding with zinc.  e)  A schematic representation of the unbound lipid switches 
(blue) in a stable liposome and membrane destabilization caused by titration with 
zinc forming zinc-bound lipids (red) that have undergone the proposed 














Figure 9.  Synthesis of zinc lipid switch ZnR1 
Conditions:  i) TsOH, EtOH, reflux ii) DIBAL-H, -78°C, dry THF iii)  NH4OAc, 






block.  While more traditional methods were originally pursued, ultimately an 
aminolysis of the ester groups was utilized.  This was accomplished by activation 
of the tail precursor dodecylamine with DIBAL-H.  Usually, DIBAL-H is used as a 
reducing agent.  Here, as exemplified in the work by Huang et al where they 
prepared a number of ethylbenzoate derivatives via organometallic complexes of 
various amines with DIBAL-H, it is used to activate an amine for aminolysis of an 
ester.88 This was key to overcoming previous complications with the addition of the 
tails.  Other synthetic approaches involved proceeding through a hydrolyzed 
intermediate of the triester Z1.3.  This intermediate, bearing three carboxylic acid 
functionalities, was very polar causing solubility issues as well as problems in the 
purification of said intermediate (see further discussion below).  By utilizing these 
aminolysis conditions, we were able to bypass that troubled intermediate and 
proceed directly to the desired amide.  This reaction also utilized an excess of a 
very reactive species, the organometallic complex, leading to full conversion of the 
triester to triamide, which was key to completion of this synthesis, as other 
synthetic methods, described below, failed to effect conversion of all three tail 
precursor units to the desired amide bonds.  All of these considerations together 
led to the aminolysis method being an overall better route to pursue for completion 
of the target lipid.     
2.5.2. Alternate Pathways to ZnR1 
In the pursuit of lipid ZnR1, many synthetic routes were taken.  Alternate pathways 
yielding interesting intermediates are given below.  These attempts were focused 
on either first constructing the TPA core and then adding the alkyl tail units, or vice 
versa.    
 
An alternate attempt to synthesize triester compound Z1.3 (Figure 10) was aimed 
at forming the TPA core via successive SN2 substitutions to synthesize the central 
tertiary amine.  This approach was hindered by the instability of intermediates 












Figure 10.  Alternate synthetic pathway to lipid intermediate Z1.3.   
Conditions: i) NaBH4, CaCl2, 0°C, degassed EtOH ii) PBr3, dry DCM iii) p-TsCl, 
TEA, DMAP, dry DCM iv) NaN3, dry DMF, 85°C v) 10% Pd/C, H2, EtOAc vi) Z1.5 





which led to no quantifiable conversion of these intermediates to the desired 
tertiary amine core.  These synthetic approaches will be discussed next. 
 
The alternative synthesis of intermediate Z1.3 began with a selective reduction of 
intermediate Z1.1.  The diester was selectively reduced at the 2-position adjacent  
to the pyridine nitrogen through the use of CaCl2 to chelate that specific ester.  This  
allowed for the selective reduction to an alcohol at the 2-position over the other 
available ester at the 4-position.85  This reduction proceeded well to give 
intermediate Z1.4.  The alcohol functionality was then transformed to a leaving 
group as bromine or tosylate in intermediates Z1.5 and Z1.6, respectively.  To 
install the necessary nitrogen into the organic skeleton, a substitution reaction with 
sodium azide quantitatively gave intermediate Z1.7, which was reduced to primary 
amine Z1.8 through palladium catalyzed hydrogenation.  Then, the primary amine 
of compound Z1.8 was reacted with two equivalents of either compound Z1.5 or 
Z1.6 to target triester Z1.3.  This final successive SN2 reaction was not successful 
due to the instability of intermediates with a leaving group at the pseudo benzylic 
position of the pyridine ring.  This led to poor to no conversion to target compound 
Z1.3.  It was then that the reductive amination pathway as described in the previous 
section was designed and pursued successfully, effectively bypassing the unstable 
intermediates and shortening the overall synthesis of Z1.3 from 6 to 3 steps.   
 
With intermediate Z1.3 in hand, a number of methods for incorporating the alkyl 
tails were considered (Figure 11).  The most classical way to construct an amide 
bond is through the activation of a carboxylic acid precursor with carbodiimide 
chemistry and subsequent attack by an amine yielding the desired amide bond.  
The required carboxylic acid precursor, Z1.9, proved difficult to purify and collect 
due to the polarity of the three carboxylic acid moieties within the molecule.  This 
led to a thorough search of the literature to devise a new tactic for the incorporation 
of the three alkyl tail units.  Kim et al published the direct amidation of various 











Figure 11.  Alternate pathways for the synthesis of lipid ZnR1 from common intermediate Z1.3.   
Conditions:  i) 2 M KOH, THF, 100°C ii) DCC, dodecylamine, DMAP  iii) 1) SOCl2, DCM 2) Dodecylamine, TEA, dry 




presence of KOtBu under a proposed peroxide mediated mechanism.89  These 
were achieved in good yields over short time periods, 5-60 minutes in most cases.  
However, the application of these conditions to triester Z1.3 did not yield the 
desired amide bonds.  Next, an acid chloride version of Z1.3 was targeted to 
increase the reactivity of the carbonyl groups.  To this end, intermediate Z1.3 was 
converted to carboxylic acid Z1.9 by refluxing with KOH and used without 
purification beyond an extractive workup.  The triacid chloride was prepared and 
used directly for the next reaction without characterization.  Full conversion of Z1.9 
to acid chloride was monitored by the disappearance of the starting material spot 
(Z1.9) via TLC.  Subsequent reaction with dodecyl amine did not provide the target 
compound ZnR1.  Possible pitfalls of this avenue include the presence of three 
reactive or highly polar carbonyl groups attempting to couple with a long chain 
saturated amine causing solubility issues along with the inability to purify these 
highly polar intermediates.  Ultimately, due to the combination of these issues, a 
new approach was devised to incorporate the three alkyl tail units.  It was here that 
the aminolysis conditions utilizing DIBAL-H described in section 2.5.1 were applied 
successfully.     
 
Concurrent with the previously described syntheses, attempts to construct 
individual pyridine tail units and then trimerize them were also considered (Figure 
12).  Again, the classical approach of carbodiimide coupling was pursued first.  
First, the ester of intermediate Z1.4 was hydrolyzed to give carboxylic acid 
intermediate Z1.10. This was coupled via carbodiimide chemistry with dodecyl 
amine.  However, this was unsuccessful and did not yield intermediate Z1.11.  The 
direct amidation with KOtBu conditions as given in the last section were applied to 
both intermediates Z1.4 and Z1.2.  The reaction with Z1.4 yielded only starting 
materials without conversion to product.  This was most likely due to the potassium 
tertbutoxide deprotonating the alcohol rather than interacting with the ester 
functional group was required for the desired transformation.  Application of the 













Figure 12.  Alternative pathways to single pyridal tail units toward ZnR1. 
a)  Formation via classical carbodiimide chemistry.  Conditions: i) 2 M KOH, THF, 
100°C ii) EDCI, dodecylamine, DMAP, dry DMF b) Formation of amide bond via 
direct amidation led to the hemiaminol Z1.14 rather than desired intermediate 






attempted conversion of Z1.2 to an acid chloride and subsequent substitution with 
dodecyl amine gave interesting results (Figure 12).  The desired single tailed 
aldehyde Z1.12 was not formed, instead the hemiaminol Z1.13 was recovered.  
This was due to the conversion of the aldehyde unit to a geminal halohydrin and 
subsequent substitution of the chloride with dodecyl amine.  Attempts to reverse 
the hemiaminol and eliminate the long chain amine were not successful and 
although this was not the desired outcome it did reveal the possibility for reactivity 
through this particular mechanism at the pyridal ethyl ester position, which could 
be useful information for future synthetic endeavors. It also supports the notion 
that previous TPA intermediate Z1.9 was probably the issue with the syntheses 
laid out in Figure 11, as the desired ester hydrolysis reaction was able proceed 
through a single version of the ester intermediate (Z1.4, Figure 12).  Through the 
investigation of parallel synthetic routes, the formation of triester intermediate Z1.3 
and direct conversion to ZnR1 via the aminolysis reaction described above 
provided the shortest and most straightforward route for the synthesis of the 
desired lipid.   
2.5.3. Liposomal Release Studies with ZnR1 
With lipid target ZnR1 successfully synthesized, next began liposomal release 
experiments.  Liposomes containing 0, 10, and 20% of ZnR1 were investigated for 
their triggered release potential. 
 
For all experiments, liposomes were formed via the thin film hydration method.23  
Stock solutions of lipids ZnR1 (5mM), PC (32mM), and hydrophobic dye nile red 
(5mM) were prepared in chloroform, with ZnR1 in a 1:1 mixture of chloroform and 
methanol.  Lipids were aliquoted to clean, dry vials to prepare the desired lipid 
ratios at 2mM total lipid content.  For example, to create liposomes containing 10% 
ZnR1 lipid, 13.3 μL of PC stock, 10 μL of ZnR1 stock, and 5 μL of nile red stock 
were combined in a clean, dry vial.  The resulting solution was dried under a stream 




then dried further under high vacuum to assure complete removal of residual 
solvent.  Then, 250 μL of MilliQ purified water was added to the vial and the film 
was hydrated at 60°C for 45 minutes with vortexing every 15 minutes.  The 
resulting liposome solution was put through ten freeze-thaw cycles with a dry 
ice/acetone bath and 60°C water bath.  This gave a solution of non-uniform size 
or lamellarity vesicles which were then extruded 15 times through a 200 nm 
polycarbonate membrane to yield a solution of 200 nm diameter liposomes 
encapsulating nile red.  These same methods of thin film hydration and extrusion 
were used to prepare all liposomes for this work.   
 
To determine the release profile of ZnR1, prepared liposomes were titrated with 
Zn2+ wherein release would be indicated by a decrease in fluorescence upon 
precipitation of the hydrophobic dye with its release into the aqueous media.  The 
choice of the zinc salt for the titration solution preparation became quite important 
in this case.  In aqueous solutions of ZnCl2, insoluble precipitates of zinc 
compounds are formed, lowering the Zn2+ concentration.  Also, aqueous ZnCl2 
solutions are more acidic (pH ~2) than those formed from other zinc salts.  0.5 and 
0.1 M solutions of zinc acetate in MilliQ water were found to have a pH of ~7, which 
was more desirable for our uses. 
 
Initial fluorescence studies were completed with liposome solutions of 0, 10, and 
20% ZnR1 with PC, hydrated in milliQ water.  In each case, 100μL of liposome 
solution was added to a 50μL well microcuvette.  An initial fluorescence reading 
was taken from 560 – 700 nm with excitation wavelength of 552 nm and the 
liposome solution was then titrated with a 0.1 M aqueous solution of Zn(OAc)2 to 
a total zinc concentration of 10 mM.  No significant release over the control 
liposomes (0% ZnR1) was seen for either the 10 or 20% ZnR1 liposomes.  Dilution 
studies were also conducted where 50 μL of the given liposome solution was 
diluted to a final volume of 3 mL with MilliQ water giving a lipid concentration of 




release of dye in any case.  Problems with release were attributed to the 
electronegativity of the neighboring carbonyl groups, drawing electron density from 
the TPA nitrogens.  A more electron poor TPA molecule would result in a 
dampened chelation ability and thus hamper release.  To combat this, other lipid 
skeletons were designed, as will be described in the next sections.     
2.6. Design and Synthesis of Zinc-Responsive Lipids of ZnR2 
Type 
Lipids of type ZnR2 were designed with differing tail connections.  In contrast to 
the electron withdrawing amide tails of ZnR1, these lipids exhibit a variety of bond 
types (Figure 13).  The zinc chelating core is the same, with these lipids being 
based on TPA as well.  The synthesis of these lipids proceeds through a common 
intermediate, lending the quick accumulation of target compounds via these 
methods.   
2.6.1. Synthesis of ZnR2 Type Lipids 
Synthesis of lipid ZnR2.1 (Figure 14) began with the formation of common 
intermediate Z2.1.  This is a core-first approach similar to that utilized to synthesize 
lipid analog ZnR1.  Beginning with commercially available 5-bromo-2-
pyridinecarboxaldehyde, the TPA core was constructed by sequential reductive 
aminations forming primary and secondary amine intermediates in situ, giving 
intermediate Z2.1 at a 96% yield.87  Toward ZnR2.1, the bromine functionality was  
utilized to perform a Sonogoshira coupling with 1-dodecyne.  Despite varying 
conditions, full conversion of all three bromide substitutions to alkyne tails was not 
achieved in any appreciable yield, though product was detected by mass 
spectroscopy. Other avenues were explored to increase conversion.  Rather than 
beginning with the fully constructed TPA core, individual pyridine-alkyne tail units 
were synthesized (Figure 14).  This synthesis began with the same 5-bromo-2-









Figure 13.  Structures of lipid targets ZnR2.1 – ZnR2.5.   
These lipids stem from a common TPA core intermediate.  Tails of varying 
saturation and rigidity are designed to test the dependency of release on the 













Figure 14.  Synthetic steps toward ZnR2.1 
i) NH4OAc, NaBH(OAc)3, dry DCM ii) 1-dodecyne, PdCl2(PPh3)2, CuI, 5:1 
DMF:TEA iii) Z2.2, NaBH(OAc)3, dry DCM iv) 1) Z2.2, TEA, toluene, Dean Stark 





Z2.1.  It was coupled successfully with 1-dodecyne in a palladium catalyzed cross 
coupling reaction to yield intermediate Z2.2.  One pot reductive amination 
conditions toward formation of the TPA core gave primary amine Z2.3 as the sole 
product.  Attempts to perform stepwise reductive aminations were also unable to 
proceed past the primary amine intermediate.  Tested conditions depicted in Figure 
14 include the reaction of aldehyde Z2.2 with primary amine Z2.3 with sodium 
trisacetoxyborohydride as the reducing agent, which gave only recovery of starting 
materials and none of the desired product, ZnR2.1.  Stepwise reductive aminations 
with sodium borohydride as the reducing agent were also attempted, but only the 
starting primary amine Z2.3 and the reduced version of aldehyde Z2.4, where the 
aldehyde was reduced to a primary alcohol, were recovered in any case.  The 
amphiphilic nature of the starting materials may cause solubility issues hampering 
the desired reactions.  It was due to the hinderance of these steps that other lipid 
targets were also pursued.   
 
Lipid ZnR2.2 was targeted next.  Common intermediate Z2.1 was coupled with 
boronic acid precursor trans-octenylboronic acid via a palladium catalyzed Suzuki-
Miyaura coupling reaction, modified from the similar reaction scheme of Bravin et 
al to suit these specific synthetic needs.87  The successful coupling gave lipid 
ZnR2.2 at 34% yield (Figure 15).  Based upon this success, other boronic acid 
derivatives can be utilized for the Suzuki-Miyaura coupling step to target TPA core 
lipids ZnR22.3-ZnR2.5.          
2.6.2. Liposomal Studies with ZnR2 Type Lipids  
With the completion and characterization of ZnR2.2, it was immediately utilized for 
liposomal studies.  Lipid ZnR2.2 was prepared at a 10 mM stock in chloroform and 
liposomes were formed by the same techniques from section 2.5.3.  Liposomes of 
0, 10, and 20% ZnR2.2 hydrated with MilliQ water were prepared at 2 mM and 
0.033 mM dilute liposome samples, as previously described.  Titration with 















Figure 15.  Synthesis of ZnR2.2  






the proposed release method.  The draw of TPA was its selectivity for zinc over 
other divalent metal ions.  This selectivity is attributed to the small binding pocket 
of the TPA core as compared to TPEN along with a more desirable pKa.79  This 
could be negatively impacting the conformational change aspect of this platform.  
The TPA unit would idealy be presented at the aqueous interface of the liposome 
surface where, based on hydrophilicity, the nitrogens of the pyridine rings along 
with the central tertiary nitrogen could be oriented upward, essentially preforming 
a binding pocket for zinc to fall in to (Figure 16).  If this is the case, there would not 
be a large conformational change between bound and unbound states of the 
switch.  This would explain the failure of both ZnR1 and ZnR2.2.  There also exists 
a pH dependency of these lipid analogs.  At low pH, 6.2 or below, a large portion 
of TPA becomes protonated.79  As modeled in Figure 16, protonation of the central 
nitrogen of TPA will facilitate the preformation of the proposed zinc binding pocket, 
further dampening the conformational change aspect of these TPA based lipid 
analogs. 
 
To determine if the lipids were capable of chelating zinc and to rule out a lack of 
binding as the reason for lack of release, UV-Vis studies were performed.  
Solutions of 40 μM of lipids ZnR1 and ZnR2.2 were prepared in pH 7.45 PIPES 
buffer.  An initial scan of UV-Vis absorbance was taken.  Then, a sample that was 
40 μM in lipid and 200 μM in ZnCl2 was prepared and UV-Vis spectra were 
collected at time 0, 10, and 20 minutes.  ZnR1 did not exhibit a specific pattern in 
changes, further strengthening the previous assertion that its more electron 
withdrawn TPA core will not bind zinc strongly.  However, ZnR2.2 showed a steady 
decrease in absorbance at ~283 nm.  This can be attributed to the chelation of zinc 
decreasing the absorption of the TPA core.79 This indicates that lipid ZnR2.2 is 
capable of chelating zinc, adding more weight to the argument that the 
presentation of TPA at the surface is preformed in an ideal conformation for the 













Figure 16.  Optimal presentation of TPA core at the aqueous interface of the 
liposomal membrane 
All nitrogen units will be oriented upward to the aqueous interface, preforming a 
binding pocket for incoming Zn2+ ions (structure a).  This may not lead to a large 
conformational change of the core upon chelation (structure b), thus dampening 
release.  Protonation of the central TPA nitrogen may also lead to pre-
organization of the pyridal units (structure c) strengthening the preformed binding 





synthetic efforts to also target a different zinc chelator as the lipid core, as will be 
expanded on in the next section.       
 
To further investigate the pH dependence of the binding ability of ZnR2.2, 
liposomes composed of 0, 25, 50 and 75% ZnR2.2 with PC were prepared in pH 
7 PIPES buffer.  Though the same thin film hydration and extrusion methods were 
followed as before, no fluorescence, by extension no encapsulated nile red 
lipophilic dye, was detected via fluorimetry experiments for any of the liposome 
formulations in either concentrated or dilute liposome samples.  This led to the 
determination that PIPES buffer will not be suitable for liposome studies.  Next, 
tris-buffered saline (TBS) at pH 8 was used to hydrate the lipid films.  Liposomes 
of 0, 25, 50, 75, and 95% ZnR2.2 were formed at 2 mM lipid content as previously 
described and 100 μL of the liposome solution was titrated with aqueous 0.1 M 
Zn(OAc)2 to a total concentration of 10 mM Zn2+.  Under these conditions, an 
increase in release was seen for the liposomes composed of 50% or more of lipid 
switch with PC when compared to control liposomes (Figure 17).  While the release 
was not extensive, at only 13, 17, and 29% release for 50, 75, and 95% ZnR2.2, 
respectively with background release at 9% in absence of trigger lipid, these 
results indicated that lipid ZnR2.2 is able to induce membrane destabilization in 
the presence of increased concentrations of zinc ions.  These preliminary results 
are indicative that pH control of the liposomal solution is important to the chelation 
ability of the TPA based lipid switches.  From here, further changes to the liposome 
composition were studied to see the effects on dye release properties. 
 
Phosphatidyl ethanolamine (PE) is a non membrane forming lipid, however, when 
mixed with other lipids it can form stable membranes.  For the following studies, 
the incorporation of ZnR2.2 was held constant at 50% while the amounts of PE 
and PC were varied.  PE was incorporated at 10, 25, and 50% with the remaining 
percentage being made up of PC.  The lipid films were formed by the same protocol 




composed of 50% PE and 50% ZnR2.2 did not form liposomes.  Titration data for 
the other liposome preparations is given in Figure 17.  It was seen that 
incorporation of 25% PE was optimal for release with 41 % release seen for these 
liposomes.  This was a large increase over liposomes containing 50% synthetic 
lipid in the absence of PE which saw only 13% release.  It is assumed that the 
incorporation of PE predisposed the liposomes fusion and membrane disruption, 
making the small hypothesized conformational change previously postulated in 
Figure 16 a large enough factor to effect appreciable release.  Still, a more effective 
conformational lipid switch was desired, so other lipid analogs were designed as 







Figure 17.  Dye release profile of lipid switch ZnR2.2 
TOP:  Liposomes composed of PC and lipid analog ZnR2.2.  Appreciable release 
was only seen at high percentages of ZnR2.2 where liposomes of 95% ZnR2.2 
gave 29% release.  BOTTOM:  Incorporation of PE into the liposomal formulations 
decreased the required synthetic lipid content while increasing dye release.  
































PC based liposomes, TBS buffer pH 8
100% PC, 0% ZnR2.2
75% PC, 25% ZnR2.2
50% PC, 50% ZnR2.2
25% PC, 75% ZnR2.2
































PC & PE based liposomes, TBS buffer pH 8
75% PC, 25% PE,
0% ZnR2.2
90% PC, 10% PE,
0% ZnR2.2
25% PC, 25% PE,
50% ZnR2.2





2.7.   Design and Synthesis of Zinc-Responsive Lipids of ZnR3 
Type 
With the limited release of the TPA based lipid switches, TPEN was next targeted 
as a lipid core ion chelator.  It was hypothesized that due to the presentation of 
TPA at the surface of the liposomal membrane, there may not be a significant 
conformational change with chelation of zinc.  The use of TPEN, however, could 
change that as it was envisaged that TPEN based lipids, when inserted into the 
membrane, would have greater separation between the pyridal units of the 
chelating core than those in the TPA based lipid analogs.  Upon treatment with 
zinc, it is hypothesized that these units would have to come in closer proximity in 
order to properly chelate an ion (Figure 18).  This should cause a large enough 
conformational change in the lipid skeleton to disturb the membrane thus causing 
release of cargo.  As previously described, TPEN has a higher affinity for zinc (0.3 
fM) as compared to TPA (10 pM) though it is less selective among other divalent 
metal cations.79  This is also advantageous as the increased affinity will potentiate 
greater chelation ability.  These structural and affinity differences will be beneficial 
to our goal of designing an effective lipid switch.  Similar chemistry to that used to 
synthesize lipid ZnR2.2 will be utilized to form the TPEN core and attach a variety 
of alkyl tails to quickly and efficiently build a number of lipid skeletons.  The 












Figure 18.  TPEN chelation of zinc and structures of lipid analogs ZnR3.1 – 
ZnR3.4 
a)  A greater potential for conformational change and membrane disruption is 
hypothesized for TPEN based lipid switches as compared to TPA based lipid 
switches.  R= alkyl tail.  b)  Target structures of TPEN lipid analogs designed 
similarly to ZnR2 type lipids.  These lipids are based on a common TPEN zinc 




2.7.1. Synthesis of ZnR3 Type Lipids 
The synthesis of the TPEN core was pursued by multiple routes (Figure 19).  The 
first route to the TPEN core began with the reduction of common starting material 
5-bromo-2-pyridinecarboxaldehyde to transform the aldehyde functionality to an 
alcohol, Z3.1.  This alcohol intermediate was then chlorinated to give intermediate 
Z3.2.  Coupling of chloride Z3.2 with ethylenediamine was attempted with various 
basic conditions including NaOH90 and K2CO3, neither of which successfully 
yielded the target TPEN unit Z3.3.  Another route to intermediate Z3.3 included the 
stepwise formation of secondary amine Z3.4 through successive reductive 
aminations with ammonium acetate as the nitrogen source and sodium 
borohydride as the reducer.  However, the initial primary amine was not recovered.  
A one pot reductive amination was also pursued utilizing a weaker hydride reducer 
in sodium triacetoxyborohydride which yielded tertiary amine Z2.1 as the main 
product rather than the desired secondary amine Z3.4.  The next plausible route 
that was designed was to synthesize primary amine Z3.7 through an azide 
reduction and then couple that amine with the readily available aldehyde precursor 
through a reductive amination to give secondary amine Z3.4.  This synthetic route 
began with alcohol intermediate Z3.1, synthesized as before, which was then 
activated by transformation into tosylate Z3.5.  Substitution of the tosylate with 
sodium azide was successful in installing the required nitrogen unit.  The azide can 
then be reduced via palladium catalyzed hydrogenation to give primary amine  
Z3.7.  This will then be coupled with the readily available aldehyde to give 
secondary amine Z3.4.  To construct the TPEN core, intermediate Z3.4 will be 
coupled with dibromoethane in a double substitution reaction to give common 
intermediate Z3.3.  When the TEPN core intermediate is successfully synthesized 
it will be coupled with the desired boronic acid alkyl tail precursor to yield the target 
lipid analogs, ZnR3.1 – ZnR3.4.  Lipid analog ZnR3.1 will be targeted first as it is 
analogous to ZnR2.2 which performed well in the TPA based studies.  Facile 
switching of boronic acid functionality will provide quick access to the rest of the 





Figure 19.  Synthetic routes toward TPEN based lipid analogs 
Various synthetic routes to synthetic intermediate Z3.3 and lipid analog ZnR3.1.  Conditions:  i) NaBH4, EtOH, 0°C ii) 
SOCl2, toluene iii) ethylenediamine, NaOH(aq), DCM90  iv) ethylenediamine, K2CO3, MeCN  v) NH4OAc, NaBH(OAc)3, 
DCM  vi) 1) NH4OAc, DCM, NaBH4 2) 5-bromo-2-pyridinecarboxaldehyde, DCM, NaBH4  vii) 1,2-dibromoethane, K2CO3, 
MeCN  viii) DMAP, TEA, pTsCl, DCM ix) NaN3, DMF x) 10% Pd/C, H2  xi) 5-bromo-2-pyridinecarboxaldehyde, EtOH, 




target lipid skeletons.  As these targets are successfully synthesized, they will be 
applied in liposomal release studies to determine their release characteristics.   
 
Upon completion of synthesis of the TPEN based lipid analogs the optimized dye 
release conditions as determined in the TPA based studies of section 2.6.2 will be 
applied with formation of 200 nm liposomes composed of trigger lipid, PC, and/or 
PE in TBS.  The difference in pKa of TPEN as compared to TPA may influence the 
release profile and binding ability of the second set of analogs (ZnR3 type), so 
determination of the optimal conditions for each lipid type may be required.  Taking 
all of the experimental optimization into account, the TPEN lipid switches are 
hypothesized to have a greater potential for release than their smaller TPA 
counterparts due to their higher propensity for conformational change upon ion 
chelation.  The exact release profiles will be determined upon successful synthesis 
of each analog 
2.8. Summary and Future Work 
Molecular recognition as stimuli for the release of payload from a therapeutic 
liposome represents a new level of targeted therapeutics.  The ability to harness 
a unique physiological aspect of a disease for treatment allows for less off target 
interactions and a more concise treatment.  Toward this end, this work proposed 
a number of synthetic lipid switches for the recognition of zinc.  Based on well-
known zinc chelators, TPA and TPEN, it was envisioned that upon recognition of 
zinc there would be a conformational change within the lipid causing it to become 
a non-bilayer lipid.  This would ideally destabilize the membrane and potentiate 
cargo release.    
 
Currently, of the available completed lipid switches only ZnR2.2 causes cargo 
release.  This required a significant amount of synthetic lipid which has been 
attributed to the way in which the TPA based lipids present themselves at the 




presented in such a way that they readily bind with zinc without having to rotate 
within the membrane.  This setback was countered with the design of TPEN 
based lipid switches which have the potential for a greater conformational 
change upon chelation of zinc.  Future work with this research will include 
completion of the synthesis of compounds ZnR2.3-ZnR2.5 and further liposomal 
studies of these lipid switches along with the completed lipid ZnR2.2.  
Furthermore, the completion of the synthesis of the panel of TPEN lipids ZnR3.1-
Znr3.4 will provide a large panel of lipid switches for study of their cargo release 
profiles.  Taken together, these lipid conformational switches will provide new 
insights into the possibilities of triggered liposomal release.   
 
2.9. Synthetic Details and Compound Characterization 
2.9.1. General Experimental Information 
Reagents and solvents were generally purchased from Acros, Aldrich, or Fisher 
Scientific and used without further purification.  PC (ʟ-α-phosphatidylcholine, mixed 
isomers from chicken eggs) was purchased from Avanti Polar Lipids, Inc.  Dry 
solvents were obtained from a Pure solvent delivery system purchased from 
Innovative Technology, Inc.  Column chromatography was performed using 230-
300 mesh silica gel purchased from Sorbent Technologies.  NMR spectra were 
obtained using Varian Mercury Vx 300 MHz and Varian 500 MHz spectrometers.  
Mass spectra were obtained with JEOL DART-AccuTOF and Q-Star XL 
quadrupole time-of-flight hybrid mass spectrometers (Applied Biosystems, Foster 
City, CA).  Liposome extruder and polycarbonate membranes were obtained from 
Avestin (Ottawa, Canada).  Ultrapure water was purified via a Millipore water 





2.9.2. Synthetic Details:  Z1 Compounds 
 
Diethylpyridine-2,4-dicarboxylate (Z1.1)85 
Commercially available 2,4-pyridine dicarboxylic acid (150.0 mg, 0.90 mmol, 1.0 
equiv) and para-toluenesolufonic acid (pTsOH, 342.6 mg, 1.80 mmol, 2.4 equiv) 
were dissolved in 15 mL EtOH and refluxed for 24 h.  The reaction mixture was 
then subjected to rotary evaporation to remove the solvent.  The residue was 
dissolved in 15 mL of CHCl3 and washed with saturated NaHCO3 (15 mL).  The 
aqueous layer was extracted with 3 x 15 mL CHCl3.  The organics were combined, 
dried with MgSO4, filtered, and the solvent was removed by rotary evaporation.  
Compound Z1.1 was obtained as a clear oil/ white solid (190.3 mg, 95% yield). 1H 
NMR (300 MHz, CDCl3): δ 0.96 (m, 6H), 3.99 (m, 4H), 7.53 (d, 1H, J = 5.29 Hz), 
8.07 (s, 1H), 8.41 (d, 1H, J = 4.77 Hz) 13C NMR (125 MHz, CDCl3): δ 14.17, 14.29, 
62.31, 62.3, 124.32, 126.02, 139.19, 149.14, 150.55, 164.23, 164.45. Molecular 
formula: C12H14O4.  DART-AccuTOF-Mass Spec: [M+1] predicted: 224.09173 
[M+1] found: 224.08598 
 
 
Ethyl 2-formylisonicotinate (Z1.2)86 
Compound Z1.1 (597.5 mg, 2.69 mmol, 1.0 equiv) was dissolved in 20 mL dry THF 
under stirring and nitrogen atmosphere and then cooled to -78°C in a dry ice/ 




equiv) was added dropwise to the cold, stirring solution.  The reaction was stirred 
for 2.5 h at -78°C and then poured over ice cold acetic acid:deionized water (2 
mL:10 mL) and stirred for 1 h.  The pH of the solution was next brought to ~8 by 
adding saturated NaHCO3.  The resulting solution was extracted with 3 x 15 mL 
EtOAc and the organic layers were combined, washed with 20 mL saturated 
NaHCO3, dried with MgSO4, filtered, and the solvent was removed by rotary 
evaporation.  The crude reaction mixture was purified via column chromatography 
with 10-25-50% EtOAc in hexane to provide Z1.2 as a white solid.  (300.8 mg, 65% 
yield). 1H NMR (300 MHz, CDCl3): δ 1.39 (t, 3H, J = 7.20), 4.41 (q, 2H, J = 7.22 
Hz), 8.05 (dd, 1H, J = 4.96 Hz, 1.67 Hz), 8.43 (s, 1H), 8.91 (dd, 1H, J = 4.87 Hz, 
0.81 Hz), 10.10 (s,1H)  13C NMR (75 MHz, CDCl3): δ 14.13, 62.23, 120.84, 126.84, 
139.12, 150.95, 153.62, 164.10, 192.52. Molecular formula: C10H10O3. DART-
AccuTOF-Mass Spec: [M+1] predicted: 180.06552  [M+1] found: 180.09109 
 
 
Triethyl 2,2',2''-(nitrilotris(methylene))triisonicotinate (Z1.3)87 
Compound Z1.2 (301.0 mg, 1.70 mmol, 3.0 equiv) and NH4OAc (43.2 mg, 0.48 
mmol, 1.0 equiv) were dissolved in 7 mL dry DCM and the reaction was stirred 
under N2 for 1 h.  NaBH(OAc)3 was added in 3 portions (120.1 mg, 0.57 mmol, 1.0 
equiv per addition)  and the reaction was stirred for 1 h in between each addition.  
After the final hydride addition, the reaction was allowed to stir overnight at rt under 
N2.  The solvent was removed under reduced pressure and the reaction residue 
was dissolved in 15 mL EtOAc and washed with 15 mL of 0.1 M KOH.  The organic 




pressure.  Column chromatography with 0-10% MeOH:CHCl3 gave 140.5 mg of 
the product as a clear oil (49% yield).  1H NMR (300 MHz, CDCl3): δ 1.40 (t, 9H, J 
= 6.66 Hz), 4.03 (s, 6H), 4.41 (q, 6H, J = 7.23 Hz), 7.69 (dd, 3H, J = 5.10 Hz, 1.51 
Hz), 8.07 (s, 3H), 8.67 (dd, 3H, J = 5.05 Hz, 0.73 Hz)  13C NMR (75 MHz, CDCl3): 
δ 14.15, 60.04, 61.69,  121.25, 122.40, 138.25, 149.85, 160.14, 165.18  Molecular 
formula:  C27H30N4O6.  Q-Star XL quadrupole TOF-Mass Spec:  [M+1] predicted:  




Dodecylamine (82.3 mg, 0.44 mmol, 18.0 equiv) was dissolved in 1 mL dry THF 
and the mixture was cooled to 0°C under N2.  DIBAL-H (422 μL of a 1 M in hexane 
solution, 0.42 mmol, 17.1 equiv) was added to the cooled solution and the mixture 
was stirred for 2 h while warming to rt.  Triester Z1.3 (12.5 mg, 0.02 mmol, 1equiv) 
was dissolved in 0.5 mL THF with stirring under N2.  The previous activated amine 
solution was added dropwise to triester solution via cannula.  The reaction was 
then brought to 50°C and stirred overnight under N2.  The reaction was then cooled 
to 0°C and quenched with 1 mL of 0.5 M KHSO4.  The reaction mixture was then 
extracted with 5mL DCM and the resulting aqueous layer was then extracted with 
5mL of CHCl3.  The combined organic layers were washed with 10 mL saturated 
NaCl, dried with MgSO4, filtered, and dried via rotary evaporation.  Column 




ZnR1 as a yellow oil (3.1 mg, 17% yield). 1H NMR (300 MHz, CDCl3): δ 0.71 (t, 
9H, J = 7.07 Hz), 1.10 (s, 54H), 1.49 (m, 6H), 3.25 (m, 6H), 3.88 (s, 6H), 7.47 (d, 
3H, J = 4.38 Hz), 7.79 (s, 3H), 8.23 (bs, 3H), 8.41 (d, 3H, J = 4.97 Hz)  Molecular 
formula: C57H93N7O3. Q-Star XL quadrupole TOF-Mass Spec:  [M+Na] predicted: 
946.72321 [M+Na] found:  946.7208 
 
Ethyl 2-(hydroxymethyl)isonicotinate (Z1.4)85 
Compound Z1.1 (636.0 mg, 2.86 mmol, 1.0 equiv) was dissolved in 10 mL dry, 
degassed EtOH.  The solution was cooled below 0°C in an ice/salt bath with 
stirring.  NaBH4 (64.7 mg, 1.71 mmol, 0.6 equiv) was added in small portions to 
the cooled solution to maintain temperature of -10 to 0°C.  Then, freshly crushed 
anhydrous CaCl2 (310.7 mg, 2.86 mmol, 1.0 equiv) was slowly added to the cold 
reaction.  The reaction was allowed to stir for 3 h at 0°C under N2 after addition of 
all reagents.  After 3 h of reacting, the pH of the solution was adjusted to 6 with 1 
N HCl.  Next the solution was filtered to remove solid salts and condensed under 
reduced pressure.  Column chromatography with 10-100% EtOAc:hexanes 
yielded Z1.4 as a white solid (344.6 mg, 68% yield).  1H NMR (500 MHz, CDCl3): 
δ 1.41 (t, 3H, J = 7.54 Hz), 3.57, (bs, 1H), 4.41, (q, 2H, J = 7.24 Hz), 4.83, (s, 2H), 
7.76 (d, 1H, J = 4.92 Hz), 7.82 (s, 1H), 8.69 (d, 1H, J = 4.99 Hz)  13C NMR (125 
MHz, CDCl3): δ 14.18, 61.88, 64.20, 119.75, 121.58, 138.40, 149.30, 160.20, 
164.96   Molecular formula: C10H12O3. DART-AccuTOF-Mass Spec: [M+1] 






Ethyl 2-(bromomethyl)isonicotinate (Z1.5) 
Compound Z1.4 (181.2 mg, 1.01 mmol, 1.0 equiv) was dissolved in 4mL dry DCM.  
PBr3 (1.4 mL, 14.89 mmol, 14.74 equiv) was added and the reaction was stirred 
for 6 h at rt under nitrogen.  Next, the reaction was cooled in an ice bath and 1.5 
mL methanol was added dropwise to quench any excess PBr3.  The reaction 
mixture was washed three times with water, dried with MgSO4, and the solvent 
was removed via rotary evaporation without the application of heat.  Column 
chromatography with 10-25% EtOAc:hexane yielded Z1.5 as a clear oil (60.2 mg, 
quant).  Compound Z1.5 was found to quickly decompose to a purple oil unless 
stored at -80°C.  1H NMR (300 MHz, CDCl3): δ 1.41 (t, 3H, J = 7.09 Hz), 4.41 (q, 
2H, J = 7.16 Hz), 4.60 (s, 2H), 7.76 (d, 1H, J = 4.49 Hz), 7.98 (s, 1H), 8.72 (s, 1H)  
13C NMR (75 MHz, CDCl3): δ 14.19, 33.18, 61.98, 109.99, 122.24, 138.89, 150.44, 
157.90, 164.62.  Molecular formula: C10H11BrO2.  DART-AccuTOF-Mass Spec: 
[M+1] predicted: 243.99677, 245.99472 [M+1] found: 243.99381, 245.98980 
 
 
Ethyl 2-((tosyloxy)methyl)isonicotinate (Z1.6) 
Compound Z1.4 (20.0 mg, 0.11 mmol, 1.0 equiv), DMAP (2.4 mg, 0.02 mmol, 0.2 
equiv), and TEA (16.5 μL, 0.22 mmol, 2.0 equiv) were dissolved in 5 mL dry DCM.  
pTsCl (41.9 mg, 0.22 mmol, 2.0 equiv) was added and the reaction was stirred 
overnight under N2.  Next, the reaction was diluted with 5 mL DCM and washed 




The organic layers were combined, dried with MgSO4, filtered, and the solvent was 
removed by rotary evaporation.  Purification via column chromatography with 10-
75% EtOAc:hexane gave compound Z1.6 as a white solid (17.9 mg, 49% yield).  
1H NMR (300 MHz, CDCl3): δ 1.42 (t, 3H, J = 7.16 Hz), 2.44 (s,3H), 4.42 (q, 2H, J 
= 7.20 Hz), 5.19 (s, 2H), 7.34 (d, 2H, J = 8.11 Hz), 7.78 (dd, 1H, J = 5.08 Hz, 1.58 
Hz), 7.84 (td, 2H, J = 8.39 Hz, 1.99 Hz), 7.92 (s, 1H), 8.66 (d, 1H, J = 4.91 Hz)  13C 
NMR (125 MHz, CDCl3): δ 14.19, 21.63, 62.09, 70.99, 121.30, 122.76, 128.10, 




Ethyl 2-(azidomethyl)isonicotinate (Z1.7) 
Compound Z1.5 (30.5 mg, 0.13 mmol, 1.0 equiv) and NaN3 (24.4 mg, 0.38 mmol, 
3 equiv) were dissolved in 5 mL of dry DMF.  The reaction was then heated to 85°C 
and allowed to stir overnight.  Next the reaction was diluted with 20 mL of EtOAc 
and the solvent was removed via rotary evaporation.  The reaction residue was 
dissolved in 10 mL EtOAc and washed with 10 mL water.  The aqueous layer was 
then extracted with 3 x 7 mL EtOAc.  The combined organic layers were washed 
with 5 x 10 mL ice cold water, 1 x 20 mL saturated NaCl, and then dried with 
MgSO4.  Then the reaction was filtered and the solvent was removed via rotary 
evaporation.  The target compound was obtained in a quantitative yield as a yellow 
oil (25.8 mg).  The same reaction conditions applied to Z1.6 also gave a 
quantitative transformation to Z1.7.  1H NMR (300 MHz, CDCl3): δ 1.42 (t, 3H, J = 
7.04 Hz), 4.43, (q, 2H, J = 7.11 Hz), 4.57, (s, 2H), 7.81 (dd, 1H, J = 5.03 Hz, 1.44 
Hz), 7.90 (s, 1H), 8.75 (dd, 1H, J = 5.02 Hz, 0.74 Hz).  13C NMR (125 MHz, CDCl3): 




formula: C10H11N3O2.  DART-AccuTOF-Mass Spec: [M+1] predicted: 207.08765 
[M+1] found:  207.09040 
 
 
Ethyl 2-(aminomethyl)isonicotinate (Z1.8) 
Compound Z1.7 (12.3 mg, 0.06 mmol, 1.0 equiv) was dissolved in 5 mL of EtOAc.  
10% Pd/C (2.5 mg, 20% wt of azide, 0.002 mmol Pd) was added to the reaction 
flask and the atmosphere was replaced with H2.  After 1 hour of stirring, the 
atmosphere was replaced with N2 and a second addition of Pd/C (0.8 mg, 5% wt 
of azide, 0.0008 mmol Pd) was added and the atmosphere replaced with H2.  The 
reaction was allowed to stir overnight under hydrogen atmosphere.  Next, the 
reaction was filtered through celite to remove the palladium catalyst and the 
solvent was removed via rotary evaporation.  The crude reaction mixture was 
purified via column chromatography with 5-25% MeOH:CHCl3 and compound Z1.8 
was collected as a yellow oil (4.7 mg, 40% yield).   The product gave a yellow spot 
by ninhydrin stain on TLC.  1H NMR (500 MHz, MeOD): δ 1.40 (t, 3H, J = 7.09 Hz), 
4.10 (bs, 2H),  4.42 (q, 2H, J = 7.19 Hz), 7.82 (d, 1H, J = 4.48 Hz), 7.96 (s, 1H), 
8.71 (d, 1H, J = 4.65 Hz).  Molecular formula: C10H13NO2. DART-AccuTOF-Mass 
Spec:  [M+1] predicted: 181.09715 [M+1] found: 181.10196 
 
 




Compound Z1.4 (15.6 mg, 0.09 mmol, 1.0 equiv) was dissolved in 6 mL THF:H2O 
(1:1 v/v).  Freshly ground KOH (14.5 mg, 0.26 mmol, 3.0 equiv) was added to the 
stirring reaction.  Next, the reaction mixture was heated at reflux (100°C) for 20 h.  
The reaction was then allowed to cool to rt and then further cooled in an ice bath.  
The pH of the solution was adjusted to ~4-5 with 3 N HNO3.  The solvent was then 
removed via rotary evaporation.  The solid residue remaining in the flask was 
washed with 3 x 10 mL portions of EtOH.  The ethanol washes were transferred to 
a clean flask and the solvent was removed under reduced pressure.  The resulting 
residue was dissolved in hot isopropanol and filtered.  Removal of solvent under 
reduced pressure gave compound Z1.10 as a white solid (12.2 mg, 93% yield). 1H 
NMR (300 MHz, CDCl3/MeOD):  δ 4.59 (s, 2H), 7.57 (dd, 1H, J = 5.20 Hz, 1.50 
Hz), 7.80 (s, 1H), 8.37 (d, 1H, J = 5.26 Hz).  Molecuar formula:  C8H8O3.  DART-
AccuTOF-Mass Spec:  [M+1] predicted: 154.04987 [M+1] found: 154.04561 
2.9.3. Synthetic Details:  Z2 Compounds   
 
Tris((5-bromopyridin-2-yl)methyl)amine (Z2.1)87 
5-Bromo-2-pyridinecarboxaldehyde (1.50 g, 8.06 mmol, 3.0 equiv) and NH4OAc 
(207.2 mg, 2.69 mmol, 1 equiv) were dissolved in 25 mL of dry DCM and stirred 
for 1 hour.  3 equivalents of NaBH(OAc)3 were added in 1 equiv portions ( 565.2 
mg, 2.69 mmol, per addition) with 1 h of stirring between each addition.  The 
reaction was left to stir overnight and then the solvent was removed under  
vacuum, and the residue was dissolved in 30 mL EtOAc.  The reaction was washed 




removed by rotary evaporation.  Recrystallization twice from 50:50 THF:hexane 
and rinsing with cold hexane gave the product as a white needlelike solid (1.35 g, 
96% yield).  1H NMR (300 MHz, CDCl3): δ 3.81 (s, 6H), 7.40 (d, 3H, J = 8.36 Hz), 
7.76 (dd, 3H, J = 8.22 Hz, 2.25 Hz), 8.59 (d, 3H, J = 2.31 Hz) 13C NMR (75 MHz, 
CDCl3): δ 59.26, 119.17, 124.44, 139.05, 150.22, 157.40.  Molecular formula: 
C18H15Br3N4.  DART-AccuTOF-Mass Spec: [M+1] predicted: 526.88991, 




Compound Z2.1 (25.0 mg, 0.05 mmol, 1.0 equiv), trans-octenylboronic acid (44.0 
mg, 0.28 mmol, 6.0 equiv), and K2CO3 (45.5 mg, 0.33 mmol, 7.0 equiv) were 
dissolved in a 4:2:1 mixture of DMF:toluene:deionized water under Ar.  Pd(PPh3)4 
(3.8 mg, 7 mol%) was added and the atmosphere of the reaction vessel was 
evacuated and replaced with Ar three times.  Next, the reaction was heated at 
100°C for 48 h, followed by removal of the solvent by rotary evaporation.  The 
reaction residue was dissolved in 15 mL EtOAc and was washed with 3 x 15 mL 
water.  The organic layer was dried with MgSO4, filtered, and the solvent was 
removed by rotary evaporation.  Column chromatography with 0-10% 
MeOH:CHCl3 gave the product as a yellow oil (9.9 mg, 34% yield).  1H NMR (300 




2.21 (q, 4H, J = 6.80 Hz), 3.83 (s, 6H), 6.28 (m, 6H), 7.46 (d, 3H, J = 8.09 Hz), 
7.62 (dd, 3H, J = 8.04 Hz, 2.28 Hz), 8.45 (d, 3H, J = 1.80 Hz) 13C NMR (75 MHz, 
CDCl3): δ 14.07, 22.59, 28.87, 29.14, 31.69, 33.13, 59.58, 122.86, 126.00, 131.95, 
132.89, 133.27, 147.07.  Molecular formula: C42H60N4.  DART-AccuTOF-Mass 




5-Bromo-2-pyridinecarboxaldehyde (50.0 mg, 0.27 mmol, 1.0 equiv), 1-dodecyne 
(36.3 μL, 0.27 mmol, 1.0 equiv), CuI (0.5 mg, 0.003 mmol, 1 mol% of bromide), 
and PdCl2(PPh3)2 (5.7 mg, 0.008 mmol, 3 mol% of bromide) were dissolved in 2 
mL of a mixture of dry, degassed DMF:TEA (5:1).  The reaction vessel was flushed 
with N2 and stirred overnight at 65°C.  The reaction was then cooled and diluted 
with 15 mL of water.  The mixture was extracted with 15 mL EtOAc and the organic 
layer was washed twice with 10 mL water, once with 10 mL saturated NaCl, was 
dried with MgSO4, filtered, and the solvent was removed under reduced pressure.  
Purification via column chromatography with 0-2% EtOAc:hexane yielded Z2.2 as 
a yellow oil (40.3 mg, 55% yield).  1H NMR (300 MHz, CDCl3): δ 0.86 (t, 3H, J = 
6.87 Hz), 1.26 (s, 12H), 1.44 (quint, 2H, J = 7.28 Hz), 1.62 (quint, 2H, J = 7.13 Hz), 
2.45 (t, 3H, J = 6.99 Hz), 7.80 (dd, 1H, J = 8.16 Hz, 1.72 Hz), 7.87 (d, 1H, J = 8.02 
Hz), 8.73 (s, 1H), 10.04 (s, 1H).  13C NMR (75 MHz, CDCl3): δ 4.08, 19.61, 22.65, 
28.33, 28.91, 29.08, 29.28, 29.48, 29.54, 31.95, 98.55, 120.88, 125.76, 139.25, 
150.43, 152.55, 192.60.  Molecular formula: C18H25NO. DART-AccuTOF-Mass 







Compound Z2.2 (21.7 mg, 0.08 mmol, 3.0 equiv) and NH4OAc (2.3 mg, 0.03 mmol, 
1 equiv) were dissolved in 2 mL of dry DCM and stirred for 1 h.  3 equivalents of 
NaBH(OAc)3 were added in 1 equivalent portions (6.4 mg, 0.03 mmol per addition) 
with 1 hour of stirring between each addition.  The reaction was left to stir overnight 
and then the solvent was removed under vacuum, and the residue was dissolved 
in 7 mL EtOAc.  The reaction was washed with 7 mL 0.1 M KOH three times, dried 
with MgSO4, filtered, and the solvent removed by rotary evaporation.  Column 
chromatography with 10-50% EtOAc:hexane gave Z2.3 as the major product 
(though tertiary amine ZnR1 was the desired product) as a white solid (11.7 mg, 
quant).  1H NMR (300 MHz, CDCl3): δ 0.88 (t, 3H, J = 6.81 Hz), 1.27 (s, 12H), 1.44 
(m, 2H, J = 6.96 Hz), 1.61 (quint, 2H, J = 7.13 Hz), 2.42 (t, 2H, J = 6.99 Hz), 4.74 
(s, 2H), 7.18 (d, 1H, J = 8.08 Hz), 7.67 (d, 1H, J = 8.38 Hz), 8.56 (s, 1H).  Molecular 
formula: C18H28N2. 
 





5-bromo-2-pyridinecarboxaldehyde (1.0 g, 5.38 mmol, 1.0 equiv) was dissolved in 
20 mL of EtOH and the solution was cooled to 0°C.  NaBH4 (1.1 g, 28.22 mmol, 
5.3 equiv) was added in small portions to the cooled solution to maintain a 
temperature of 0°C and then the reaction was stirred for 4 h at rt.  Next, the solvent 
was removed via rotary evaporation and the resulting residue was dissolved in 20 
mL of DCM and was washed three times with 20 mL of water.  The organic layer 
was then dried with MgSO4, filtered, and the solvent removed under rotary 
evaporation.  Z3.1 was recovered as a white solid without further purification (757.2 
mg, 75% yield)  1H NMR (300 MHz, CDCl3): δ 3.14 (bs, 1H), 4.73 (s, 2H), 7.20 (d, 
1H, J = 8.29 Hz), 7.82 (dd, 1H, J = 8.33 Hz, 2.31 Hz), 8.62 (d, 1H, 2.17 Hz)  13C 
NMR (75 MHz, CDCl3): δ 63.88, 119.07, 121.76, 139.38, 149.59, 157.71  
Molecular formula:  C6H6BrNO 
 
 
Z3.1 (757.2 mg, 4.03 mmol, 1.0 equiv) was dissolved in 20 mL of dry toluene.  
SOCl2 (877.0 μL, 12.09 mmol, 3.0 equiv) was added dropwise to the solution of 
alcohol Z3.1 in toluene and allowed to stir for 3 h at rt then quenched with 20 mL 
of saturated NaHCO3, extracted three times with 20 mL of DCM, and the combined 
organic fractions were dried with MgSO4, filtered, and the solvent was removed via 
rotary evaporation.  Column chromatography with 10-50% acetone:hexane gave 
compound Z3.2 as a pale yellow oil (396.5 mg, 48% yield)  1H NMR (300 MHz, 
CDCl3): δ 4.57 (s, 2H), 7.31 (d, 1H, J = 8.38 Hz), 7.77 (dd, 1H, J = 8.33 Hz, 2.47 
Hz), 8.56 (dd, 1H, J = 2.42 Hz, 0.57 Hz)  13C NMR (75 MHz, CDCl3): δ 45.94, 






Z3.1 (565.4 mg, 3.00 mmol, 1.0 equiv), DMAP (73.5 mg, 0.60 mmol, 0.2 equiv),  
and TEA (836.3 uL, 6.00 mmol, 2.0 equiv) were dissolved in 30 mL dry DCM then 
pTsCl (1.1 g, 6.00 mmol, 2.0 equiv) was added and the reaction was stirred under 
N2 overnight.  Then, the reaction was transferred to a separatory funnel, washed 
twice with 20 mL 1N HCl, and the aqueous fractions washed thrice with 20 mL 
DCM.  The organic fractions were combined, dried with MgSO4, filtered, and the 
solvent was removed under reduced pressure.  Column chromatography with 10-
50% EtOAc:hexane gave the desired product as a white solid (5% yield).  1H NMR 
(300 MHz, CDCl3): δ 2.44 (s, 3H), 5.09 (s, 2H), 7.33 (m, 3H), 7.81 (d, 1H, J = 8.33 
Hz), 8.56 (s, 1H)  13C NMR (75 MHz, CDCl3): δ 21.64, 71.00, 120.42, 123.19, 




Z3.5 (47.5 mg, 0.14 mmol, 1.0 equiv) and NaN3 (27.1 mg, 0.42 mmol, 3.0 equiv) 
were dissolved in 10 mL of dry DMF and stirred at 85°C under nitrogen overnight.  
Then the reaction was diluted with 60 mL EtOAc and then the solvent was removed 
by rotary evaporation.  The resulting residue was dissolved in 25 mL EtOAc, 
washed with 25 mL of water, then the aqueous layer was extracted three times 
with 20 mL of EtOAc.  The combined EtOAc fractions were washed five times with 
ice water, once with 20 mL of saturated NaCl, dried with MgSO4, filtered, and the 




yellow-orange solid without further purification for the next reaction (quant).  1H 
NMR (300 MHz, CDCl3) δ 4.45 (s, 2H), 7.25 (d, 1H, J = 8.11 Hz, overlaps with 
solvent CDCl3 peak), 7.84 (dd, 1H, J = 8.32 Hz, 2.36 Hz), 8.65 (d, 1H, J = 2.26 Hz)  
13C NMR (75 MHz, CDCl3): δ 29.68, 54.99, 119.98, 123.18, 139.57, 150.73, 154.29  
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Spectrum 3:  Mass Spectrum (JEOL DART-AccuTOF Mass Spectometer) Compound Z1.1 [M+1] predicted: 















Spectra 6: Mass Spectrum (JEOL DART-AccuTOF Mass Spectometer) Compound Z1.2 [M+1] predicted: 180.06552  















Spectrum 9:  Mass specturm (Q-Star XL quadrupole time-of-flight hybrid mass 











Spectrum 11: 1H NMR (300 MHz, CDCl3/MeOD) Compound ZnR1.  The alkyl region integrates higher than the 





Spectrum 12:  Mass specturm (Q-Star XL quadrupole time-of-flight hybrid mass 
















Spectrum 15: Mass Spectrum (JEOL DART-AccuTOF Mass Spectometer) Compound Z1.4 [M+1] predicted: 















Spectrum 18: Mass Spectrum (JEOL DART-AccuTOF Mass Spectometer) Compound Z1.5 [M+1] predicted: 

























Spectrum 23:  Mass Spectrum (JEOL DART-AccuTOF Mass Spectometer) Compound Z1.7 [M+1] predicted: 










Spectrum 25:  Mass Spectrum (JEOL DART-AccuTOF Mass Spectometer) Compound Z1.8 [M+1] predicted: 










Spectrum 27:  Mass Spectrum (JEOL DART-AccuTOF Mass Spectometer) Compound Z1.10 [M+1] predicted: 















Spectrum 30:  Mass Spectrum (JEOL DART-AccuTOF Mass Spectometer) Compound Z2.1 [M+1] predicted: 















Spectrum 33:  Mass Spectrum (JEOL DART-AccuTOF Mass Spectometer) Compund ZnR2.2 [M+1] predicted: 















Spectra 36:  Mass Spectrum (JEOL DART-AccuTOF Mass Spectometer) Compund Z2.2 [M+1] predicted: 272.20089  
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